



Evidence reviews

Evidence review

Published: 14 December 2023

www.nice.org.uk

The following document contains the evidence that was used to develop the December 2023 recommendations:

- [Escalation of lipid-lowering treatment for secondary prevention of CVD](#)

The following documents contain the evidence that was used to develop the May 2023 recommendations:

- [CVD risk assessment tools: primary prevention](#)
- [Dietary cholesterol strategies](#)
- [Statins: efficacy and adverse effects](#)

These documents preserve evidence reviews and committee discussions for areas of the guideline before 2023:

- [Full guideline](#)
- [Appendices](#)

Other supporting evidence

- [Methods for evidence reviews A to C](#)
- [Methods for evidence review D](#)
- [Cost-utility analysis](#)
- [Network meta-analysis](#)